A Phase 3 interventional study of Brentuximab Vedotin and Methotrexate in Primary Cutaneous Anaplastic Large Cell Lymphoma, Mycosis Fungoides and Cutaneous T-Cell Lymphoma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 41 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-05.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 360 studies in Mycosis Fungoides with a site in United States — 24 open to participants now, 36 under way, none of them phase 3. Mycosis Fungoides · United States.
Among the 360 studies in Mycosis Fungoides with a site in United States, this one is the 23rd largest by enrollment of the 279 interventional ones that give a count, is one of 9 that started in 2012, is one of 19 in phase 3, and was the 266th registered.
447 studies on the registry are indexed under Mycosis Fungoides; 42 are open to participants now.
Browse Mycosis Fungoides studies →24 of the 360 studies in Mycosis Fungoides with a site in United States are open now. Recruiting first, the newest first:
Kyowa Kirin, Inc. · Sites in United States, Italy, Spain
Ages 18+
Prescient Therapeutics, Ltd. · Sites in United States, Australia, France and 1 more country
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18+
University of California, Irvine · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 30 Mycosis Fungoides studies recruiting now, 25 (83%) set no upper age limit and 1 (3%) stops at 75 or younger; 2 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
360 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 164 · Phase 2 135 · Phase 3 20 · Phase 4 4
First in 1988; this study’s year is marked. 9 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 131 is above the median of 34 across 321 interventional studies indexed under Mycosis Fungoides.
Median enrollment 32 across the 279 interventional studies, 65 across the 34 observational. Of the 301 that completed or were terminated, 95 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 360 have an industry lead sponsor. The 10 most frequent:
This study is registered under Millennium Pharmaceuticals, Inc., one of the names counted as Takeda. Under that name alone:
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
Takeda has 1 study filed under Mycosis Fungoides — fewer than ten, so there is no comparison to draw.
12 of the studies in Mycosis Fungoides with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04256018Stanford UniversityMogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome | 2026-12 |
| NCT07003100City of Hope Medical CenterA Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab | 2027-01-12 |
| NCT05357794M.D. Anderson Cancer CenterEffectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides | 2027-01-30 |
| NCT05944562Washington University School of MedicineTulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome | 2027-02-28 |
| NCT05680558Columbia UniversityPhotopheresis in Early-stage Mycosis Fungoides | 2027-03 |
Add all 12 to your calendar (.ics) → With an account.
Among the 360 studies in Mycosis Fungoides with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine objective response rate (ORR), lasting at least 4 months (ORR4), with brentuximab vedotin in participants with cluster of differentiation antigen 30 positive (CD30+) cutaneous T-cell lymphoma [mycosis fungoides (MF) and primary cutaneous anaplastic large cell lymphoma (pcALCL) ]compared to that achieved with therapy in the control arm.
The drug being tested in this study is called brentuximab vedotin. Brentuximab vedotin is being tested to treat people who have CD30+ cutaneous T-cell lymphoma (mycosis fungoides and primary cutaneous anaplastic large cell lymphoma). This study will look at the overall response of people who took brentuximab vedotin compared to people who took methotrexate or bexarotene as standard care.
The study enrolled 131 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups-which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):
This multicenter trial is being conducted worldwide. The overall time to participate in this study is approximately 6 years. Participants will make multiple visits to the clinic every 12 weeks for a minimum of 24 months after the end of treatment (EOT) visit, and then every 6 months until death, study closure, or 6 years after enrollment of the last participant.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Site personnel will explain the trial in detail and answer any question you may have if you do qualify for the study. You can then decide whether or not you wish to participate. If you do not qualify for the trial, site personnel will explain the reasons.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brentuximab vedotin 1.8 mg/kg, intravenous over approximately 30 minutes, once on Day 1 of each 21-day cycle and may continue as monotherapy for up to a total of 16 cycles (48 weeks).
Drug: Brentuximab Vedotin
Methotrexate 5 to 50 mg, tablets, orally, once weekly (dose adjustment is guided by patient response and toxicity) or Bexarotene 300 mg/m\^2, tablets, orally, once daily with meals for up to 48 weeks.
Drug: Methotrexate · Drug: Bexarotene
Brentuximab vedotin intravenous injection.
Also known as: SGN-35
Methotrexate tablets.
Bexarotene tablets.
Percentage of Participants Achieving an Objective Response That Lasts at Least 4 Months (ORR4)
ORR4 was determined by an Independent Review Facility (IRF) based on Global Response Score (GRS) which consisted of a skin assessment by the investigator using the modified severity-weighted assessment tool (mSWAT), nodal and visceral radiographic assessment by an IRF and for the participants with mycosis fungoides (MF) only, detection of circulation Sezary cells. Participants whose first response occurred after the start of subsequent anticancer therapy were excluded. Response Criteria was based on International Society for Cutaneous Lymphomas (ISCL), United States Cutaneous Lymphoma Consortium (USCLC) and Cutaneous Lymphoma Task Force (CLTF) of the European Organisation for Research and Treatment of Cancer (EORTC) Consensus guidelines (Olsen, 2011).
Time frame: Each Cycle until disease progression, death End of treatment (Median overall follow-up 38.8 months)
Percentage of Participants Achieving a CR
Complete Response (CR) was determined by the IRF based on Global Response Score (GRS) which consisted of a skin assessment by the investigator using the modified severity-weighted assessment tool (mSWAT), nodal and visceral radiographic and for the participants with mycosis fungoides (MF) only, detection of circulation Sezary cells. Response Criteria was based on ISCL, USCLC and CLTF of the EORTC Consensus guidelines (Olsen, 2011).
Time frame: Each Cycle until disease progression, death or data cutoff (Median overall follow-up 38.8 months)
Progression-Free Survival (PFS)
PFS was assessed by the IRF and is defined as the time from randomization until disease progression or death due to any cause, whichever occurs first. Disease progression was based on ISCL, USCLC and CLTF of the EORTC Consensus guidelines (Olsen, 2011).
Time frame: Until disease progression, death or data cutoff (Median PFS follow-up of 38.8 months)
Maximum Change From Baseline in Symptom Domain Score of the Skindex-29 Questionnaire
Skindex-29 is a 29-item dermatology-specific health-related quality of life (HRQoL). The Skindex-29 incorporates a 28-day recall period and consists of 3 domains: symptoms, emotions, and functioning. The domain scores and an overall score are expressed on a 100-point scale, from 0 to 100 with higher scores indicating lower levels of health- HRQoL. A negative change (reduction) from Baseline indicates improvement.
Time frame: Baseline up to End of Treatment (Week 52)
Duration of Response (DOR)
Duration of response was assessed by the IRF in participants with confirmed response \[CR or Partial Response (PR)\] and is defined as the time between first documentation of response and disease progression. Response Criteria was based on ISCL, USCLC and CLTF of the EORTC Consensus guidelines (Olsen, 2011).
Time frame: Until disease progression, death or data cutoff (Median follow-up 38.8 months)
DOR of Skin Response
Duration of skin response (CR and PR) was assessed by the investigator and is defined as the time between the first skin response to progressive disease in skin. Per mSWAT, CR is defined as 100% clearance of skin lesions. PR is defined as 50%-99% clearance of skin disease from Baseline; No new tumors in participants without tumors at Baseline -MF; No new tumors-primary cutaneous anaplastic large cell lymphoma (pcALCL).Progressive disease is defined as ≥ 25% increase in skin disease from baseline, or loss of response: in those with CR or PR, increase of skin score of greater than the sum of nadir plus 50% baseline score, or new tumors in participants without tumors at baseline (MF).
Time frame: Until disease progression, death or data cutoff (Median follow-up 38.8 months)
Event-Free Survival (EFS)
EFS was assessed by the IRF and is defined as the time from randomization until any cause of treatment failure: disease progression, discontinuation of treatment for any reason, or death due to any cause, whichever occurs first. Disease progression was based on ISCL, USCLC and CLTF of the EORTC Consensus guidelines (Olsen, 2011).
Time frame: From randomization until disease progression, death or data cutoff (Median follow-up 36.8 months)
Cmax: Maximum Observed Concentration for Brentuximab Vedotin
Time frame: Day 1 pre-dose and 30 minutes after infusion in Cycles 1 and 3
Ctrough: Observed Concentration at the End of a Dosing Interval for Brentuximab Vedotin
Time frame: Day 1 pre-dose of Cycles 2 and 4
Cmax: Maximum Observed Concentration for Monomethyl Auristatin (MMAE) for Brentuximab Vedotin
Time frame: Day 1 pre-dose and 30 minutes after infusion ended in Cycles 1 and 3
Ctrough: Observed Concentration at the End of a Dosing Interval for MMAE for Brentuximab Vedotin
Time frame: Day 1 pre-dose of Cycles 2 and 4
Number of Participants With Antitherapeutic Antibodies (ATA) to Brentuximab Vedotin
Blood was collected and evaluated for ATA and neutralizing ATA in all participants who received brentuximab vedotin to assess immunogenicity.
Time frame: Baseline up to End of Treatment (Week 52)
Change From Baseline in the Skindex-29 Questionnaire Total Score
Skindex-29 is a 29-item dermatology-specific health-related quality of life (HRQoL). The Skindex-29 incorporates a 28-day recall period and consists of 3 domains: symptoms, emotions, and functioning. The domain scores and an overall score are expressed on a 100-point scale, 0 to 100 with higher scores indicating lower levels of health- HRQoL. A negative change (reduction) from Baseline indicates improvement.
Time frame: Day 1 of Cycles 1, 2, 4, 6, 8, 10, 12, 14, 16, at End of Treatment (EOT) and during posttreatment long treatment follow-up (LTFU) - (Median follow-up 38.8 months)
Change From Baseline in Functional Assessment of Cancer Therapy General Questionnaire (FACT-G) Score
FACT-G is a 27-item general cancer QOL instrument completed by participants receiving cancer treatment. FACT-G incorporates a 7-day recall period and contains 4 primary subscales: Physical Well-Being (PWB; sum of 7 items, point range 0-28); Social/Family Well-Being (SWB, sum of 7-items, point range 0-28); Emotional Well-Being (EWB; sum of 6-items, point range 0-24); Functional Well-Being (FWB; sum of 7-items, point range 0-28); Fact-G total score=sum of PWB, SWB, EWB, FWB, point range 0-108. Higher scores for the total scales and subscales indicate better quality of life. A negative change (reduction) from Baseline indicates improvement.
Time frame: Day 1 of Cycles 1, 2, 4, 6, 8, 10, 12, 14, 16, at EOT and during posttreatment (LTFU) - (Median follow-up 38.8 months)
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
AEs and SAEs were assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A SAE is any AE that results in death, is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in significant disability or incapacity, is a congenital anomaly/birth defect or is a medically important event.
Time frame: First dose of study drug through 30 days after last dose of study drug (Up to 450 days)
Participants took part in the study at 34 investigative sites in Australia, Belgium, Brazil, France, Germany, Italy, Poland, Spain, Switzerland, United Kingdom, United States from 11 June 2012 to the Primary Completion data of 06 July 2018.
| Milestone | Brentuximab Vedotin | Methotrexate or Bexarotene |
|---|---|---|
| Started | 66 | 65 |
| Safety population: treated | 66 | 62 |
| Intent to treat population: cd30+ | 64 | 64 |
| Completed | 32 | 22 |
| Not completed | 34 | 43 |
| Withdrew: Reason not specified | 0 | 1 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Withdrawal by subject | 10 | 16 |
| Withdrew: Death | 20 | 25 |
| Withdrew: Died and end of study page not completed | 2 | 0 |
ORR4 was determined by an Independent Review Facility (IRF) based on Global Response Score (GRS) which consisted of a skin assessment by the investigator using the modified severity-weighted assessment tool (mSWAT), nodal and visceral radiographic assessment by an IRF and for the participants with mycosis fungoides (MF) only, detection of circulation Sezary cells. Participants whose first response occurred after the start of subsequent anticancer therapy were excluded. Response Criteria was based on International Society for Cutaneous Lymphomas (ISCL), United States Cutaneous Lymphoma Consortium (USCLC) and Cutaneous Lymphoma Task Force (CLTF) of the European Organisation for Research and Treatment of Cancer (EORTC) Consensus guidelines (Olsen, 2011).
| percentage of participants | Brentuximab Vedotin | Methotrexate or Bexarotene |
|---|---|---|
| Percentage of Participants Achieving an Objective Response That Lasts at Least 4 Months (ORR4) | 54.7 (42.5 to 66.9) | 12.5 (4.4 to 20.6) |
Complete Response (CR) was determined by the IRF based on Global Response Score (GRS) which consisted of a skin assessment by the investigator using the modified severity-weighted assessment tool (mSWAT), nodal and visceral radiographic and for the participants with mycosis fungoides (MF) only, detection of circulation Sezary cells. Response Criteria was based on ISCL, USCLC and CLTF of the EORTC Consensus guidelines (Olsen, 2011).
| percentage of participants | Brentuximab Vedotin | Methotrexate or Bexarotene |
|---|---|---|
| Percentage of Participants Achieving a CR | 17.2 (7.9 to 26.4) | 1.6 (0.0 to 8.4) |
PFS was assessed by the IRF and is defined as the time from randomization until disease progression or death due to any cause, whichever occurs first. Disease progression was based on ISCL, USCLC and CLTF of the EORTC Consensus guidelines (Olsen, 2011).
| months | Brentuximab Vedotin | Methotrexate or Bexarotene |
|---|---|---|
| Progression-Free Survival (PFS) | 16.7 (15.4 to 21.6) | 3.5 (2.4 to 4.6) |
Skindex-29 is a 29-item dermatology-specific health-related quality of life (HRQoL). The Skindex-29 incorporates a 28-day recall period and consists of 3 domains: symptoms, emotions, and functioning. The domain scores and an overall score are expressed on a 100-point scale, from 0 to 100 with higher scores indicating lower levels of health- HRQoL. A negative change (reduction) from Baseline indicates improvement.
| score on a scale | Brentuximab Vedotin | Methotrexate or Bexarotene |
|---|---|---|
| Maximum Change From Baseline in Symptom Domain Score of the Skindex-29 Questionnaire | -28.08 ± 26.863 | -8.62 ± 17.013 |
Duration of response was assessed by the IRF in participants with confirmed response \[CR or Partial Response (PR)\] and is defined as the time between first documentation of response and disease progression. Response Criteria was based on ISCL, USCLC and CLTF of the EORTC Consensus guidelines (Olsen, 2011).
| months | Brentuximab Vedotin | Methotrexate or Bexarotene |
|---|---|---|
| Duration of Response (DOR) | 15.1 (9.8 to 25.5) | 18.4 (3.5 to NA) |
Duration of skin response (CR and PR) was assessed by the investigator and is defined as the time between the first skin response to progressive disease in skin. Per mSWAT, CR is defined as 100% clearance of skin lesions. PR is defined as 50%-99% clearance of skin disease from Baseline; No new tumors in participants without tumors at Baseline -MF; No new tumors-primary cutaneous anaplastic large cell lymphoma (pcALCL).Progressive disease is defined as ≥ 25% increase in skin disease from baseline, or loss of response: in those with CR or PR, increase of skin score of greater than the sum of nadir plus 50% baseline score, or new tumors in participants without tumors at baseline (MF).
| months | Brentuximab Vedotin | Methotrexate or Bexarotene |
|---|---|---|
| DOR of Skin Response | 18.9 (15.0 to 25.7) | 18.3 (3.5 to NA) |
EFS was assessed by the IRF and is defined as the time from randomization until any cause of treatment failure: disease progression, discontinuation of treatment for any reason, or death due to any cause, whichever occurs first. Disease progression was based on ISCL, USCLC and CLTF of the EORTC Consensus guidelines (Olsen, 2011).
| months | Brentuximab Vedotin | Methotrexate or Bexarotene |
|---|---|---|
| Event-Free Survival (EFS) | 9.4 (5.9 to 11.7) | 2.3 (1.7 to 3.5) |
| ug/mL | pcALCL: Brentuximab Vedotin | MF: Brentuximab Vedotin 1.8 mg/kg |
|---|---|---|
| Cycle 1 Day 1 | 38.36 ± 9.427 | 38.40 ± 8.912 |
| Cycle 3 Day 1 | 40.14 ± 12.697 | 36.69 ± 14.249 |
| ug/mL | pcALCL: Brentuximab Vedotin | MF: Brentuximab Vedotin 1.8 mg/kg |
|---|---|---|
| Cycle 2 Day 1 | 3.57 ± 10.101 | 0.58 ± 0.517 |
| Cycle 4 Day 1 | 0.99 ± 0.528 | 0.78 ± 0.446 |
| ng/mL | pcALCL: Brentuximab Vedotin | MF: Brentuximab Vedotin 1.8 mg/kg |
|---|---|---|
| Cycle 1 Day 1 | 2.53 ± 1.382 | 3.34 ± 1.901 |
| Cycle 3 Day 1 | 2.96 ± 1.176 | 3.08 ± 1.276 |
| ng/mL | pcALCL: Brentuximab Vedotin | MF: Brentuximab Vedotin 1.8 mg/kg |
|---|---|---|
| Cycle 2 Day 1 | 0.11 ± 0.095 | 0.09 ± 0.060 |
| Cycle 4 Day 1 | 0.14 ± 0.113 | 0.11 ± 0.091 |
Blood was collected and evaluated for ATA and neutralizing ATA in all participants who received brentuximab vedotin to assess immunogenicity.
| participants | pcALCL: Brentuximab Vedotin | MF: Brentuximab Vedotin 1.8 mg/kg |
|---|---|---|
| Immunogenicity-evaluable participants | 14 | 46 |
| Baseline Negative: ATA negative | 8 | 23 |
| Baseline Negative: ATA positive | 6 | 19 |
| Baseline Negative: Transiently Positive | 4 | 9 |
| Baseline Negative: Persistently Positive | 2 | 10 |
| Baseline Negative: Neutralizing ATA Positive | 4 | 14 |
| Baseline Positive: ATA Negative | 0 | 1 |
| Baseline Positive: ATA Positive | 0 | 3 |
| Baseline Positive: Transiently Positive | 0 | 3 |
| Baseline Positive: Persistently Positive | 0 | 0 |
| Baseline Positive: Neutralizing ATA Positive | 0 | 2 |
Skindex-29 is a 29-item dermatology-specific health-related quality of life (HRQoL). The Skindex-29 incorporates a 28-day recall period and consists of 3 domains: symptoms, emotions, and functioning. The domain scores and an overall score are expressed on a 100-point scale, 0 to 100 with higher scores indicating lower levels of health- HRQoL. A negative change (reduction) from Baseline indicates improvement.
| score on a scale | Brentuximab Vedotin | Methotrexate or Bexarotene |
|---|---|---|
| Change at Cycle 2 | -5.44 ± 11.055 | -2.49 ± 11.959 |
| Change at Cycle 4 | -14.60 ± 17.488 | -6.71 ± 9.755 |
| Change at Cycle 6 | -17.59 ± 17.770 | -5.40 ± 9.758 |
| Change at Cycle 8 | -21.73 ± 18.882 | -7.28 ± 16.769 |
| Change at Cycle 10 | -22.47 ± 21.722 | -3.71 ± 21.752 |
| Change at Cycle 12 | -23.37 ± 21.555 | -5.22 ± 17.704 |
| Change at Cycle 14 | -19.72 ± 20.980 | -7.49 ± 22.463 |
| Change at Cycle 16 | -19.35 ± 18.911 | 0.75 ± 10.308 |
| Change at End of Treatment | -16.26 ± 23.281 | -0.96 ± 18.973 |
| Change at 3-6 months LTFU | -1.07 ± 3.704 | -9.48 ± 21.629 |
| Change at 6-9 months LTFU | -8.04 ± 8.800 | -9.68 ± 17.789 |
| Change at 9-12 months LTFU | -7.94 ± 15.582 | -4.93 ± 14.516 |
| Change at 12-15 months LTFU | -16.21 ± 18.438 | -11.16 ± 18.183 |
| Change at 15-18 months LTFU | -19.18 ± 19.475 | -8.53 ± 12.768 |
| Change at 18-21 months LTFU | -19.27 ± 20.962 | -5.46 ± 16.679 |
| Change at 21-24 months LTFU | -16.60 ± 19.875 | -6.86 ± 14.991 |
| Change at 24-27 months LTFU | -17.04 ± 15.982 | -9.05 ± 23.990 |
| Change at 27-30 months LTFU | -12.45 ± 19.639 | -7.97 ± 16.401 |
| Change at >30 months LTFU | -11.49 ± 22.470 | -1.07 ± 18.886 |
FACT-G is a 27-item general cancer QOL instrument completed by participants receiving cancer treatment. FACT-G incorporates a 7-day recall period and contains 4 primary subscales: Physical Well-Being (PWB; sum of 7 items, point range 0-28); Social/Family Well-Being (SWB, sum of 7-items, point range 0-28); Emotional Well-Being (EWB; sum of 6-items, point range 0-24); Functional Well-Being (FWB; sum of 7-items, point range 0-28); Fact-G total score=sum of PWB, SWB, EWB, FWB, point range 0-108. Higher scores for the total scales and subscales indicate better quality of life. A negative change (reduction) from Baseline indicates improvement.
| score on a scale | Brentuximab Vedotin | Methotrexate or Bexarotene |
|---|---|---|
| Change at Cycle 2 | 1.43 ± 10.168 | -0.37 ± 11.723 |
| Change at Cycle 4 | 1.75 ± 12.014 | 1.78 ± 10.740 |
| Change at Cycle 6 | 4.23 ± 14.257 | 2.24 ± 13.108 |
| Change at Cycle 8 | 5.96 ± 16.030 | 2.54 ± 10.809 |
| Change at Cycle 10 | 6.61 ± 16.971 | 4.38 ± 15.040 |
| Change at Cycle 12 | 7.94 ± 18.837 | 8.61 ± 21.024 |
| Change at Cycle 14 | 9.04 ± 14.104 | 10.75 ± 13.615 |
| Change at Cycle 16 | 5.08 ± 9.230 | 7.88 ± 23.432 |
| Change at End of Treatment | 0.35 ± 16.067 | -2.29 ± 17.171 |
| Change at 3-6 months LTFU | 16.00 ± 18.385 | -2.92 ± 8.367 |
| Change at 6-9 months LTFU | -0.19 ± 19.648 | -2.59 ± 12.473 |
| Change at 9-12 months LTFU | 3.62 ± 17.651 | -5.32 ± 10.555 |
| Change at 12-15 months LTFU | 8.33 ± 14.918 | -1.34 ± 11.905 |
| Change at 15-18 months LTFU | 3.03 ± 12.618 | 2.94 ± 14.756 |
| Change at 18-21 months LTFU | 3.35 ± 11.117 | -0.19 ± 14.316 |
| Change at 21-24 months LTFU | 1.51 ± 5.471 | 0.61 ± 14.505 |
| Change at 24-27 months LTFU | 4.20 ± 7.952 | 1.42 ± 17.870 |
| Change at 27-30 months LTFU | -1.57 ± 17.488 | 1.93 ± 8.716 |
| Change at >30 months LTFU | -6.22 ± 15.222 | -2.85 ± 5.518 |
AEs and SAEs were assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A SAE is any AE that results in death, is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in significant disability or incapacity, is a congenital anomaly/birth defect or is a medically important event.
| participants | Brentuximab Vedotin | Methotrexate or Bexarotene |
|---|---|---|
| AEs | 63 | 56 |
| SAEs | 18 | 18 |
Collected over All-Cause mortality: Baseline up to End of study (Up to 6 years); Serious and Other adverse events: First dose of study drug through 30 days after last dose of study drug (Up to 450 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brentuximab Vedotin | 22/66 (33.3%) | 18/66 (27.3%) | 60/66 (90.9%) |
| Methotrexate or Bexarotene | 25/62 (40.3%) | 18/62 (29%) | 51/62 (82.3%) |
| Event | Brentuximab Vedotin | Methotrexate or Bexarotene |
|---|---|---|
| PyrexiaGeneral disorders | 2/66 | 4/62 |
| SepsisInfections and infestations | 1/66 | 3/62 |
| CellulitisInfections and infestations | 2/66 | 0/62 |
| Superinfection bacterialInfections and infestations | 0/66 | 1/62 |
| UrosepsisInfections and infestations | 0/66 | 1/62 |
| ParotitisInfections and infestations | 0/66 | 1/62 |
| Periorbital infectionInfections and infestations | 0/66 | 1/62 |
| ErysipelasInfections and infestations | 0/66 | 1/62 |
| NeuralgiaNervous system disorders | 0/66 | 1/62 |
| HypernatraemiaMetabolism and nutrition disorders | 0/66 | 1/62 |
| Event | Brentuximab Vedotin | Methotrexate or Bexarotene |
|---|---|---|
| Peripheral sensory neuropathyNervous system disorders | 31/66 | 1/62 |
| NauseaGastrointestinal disorders | 24/66 | 9/62 |
| FatigueGeneral disorders | 18/66 | 18/62 |
| DiarrhoeaGastrointestinal disorders | 18/66 | 4/62 |
| HypertriglyceridaemiaMetabolism and nutrition disorders | 1/66 | 11/62 |
| VomitingGastrointestinal disorders | 11/66 | 3/62 |
| PruritusSkin and subcutaneous tissue disorders | 11/66 | 8/62 |
| AlopeciaSkin and subcutaneous tissue disorders | 10/66 | 2/62 |
| Decreased appetiteMetabolism and nutrition disorders | 10/66 | 3/62 |
| PyrexiaGeneral disorders | 9/66 | 8/62 |
Safety population included participants who received at least 1 dose of study drug, analyzed according to the actual treatment received (n=66,62). Intent-to-treat population (ITT) population included all participants who were identified as CD30+ by the Ventana anti-CD30 (Ber-H2) assay and were randomized to treatment (n=64,64).
| Age, Continuous(years) | Brentuximab Vedotin | Methotrexate or Bexarotene | Total |
|---|---|---|---|
| Mean | 59.4 ± 13.80 | 56.6 ± 14.43 | 58.0 ± 14.12 |
| Sex: Female, Male(Participants) | Brentuximab Vedotin | Methotrexate or Bexarotene | Total |
|---|---|---|---|
| Female | 33 | 28 | 61 |
| Male | 33 | 34 | 67 |
| Race/Ethnicity, Customized(participants) | Brentuximab Vedotin | Methotrexate or Bexarotene | Total |
|---|---|---|---|
| White | 56 | 53 | 109 |
| Black or African American | 3 | 3 | 6 |
| Asian | 1 | 5 | 6 |
| Not reported | 3 | 1 | 4 |
| Other | 1 | 2 | 3 |
| Race/Ethnicity, Customized(participants) | Brentuximab Vedotin | Methotrexate or Bexarotene | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 6 | 8 |
| Not Hispanic or Latino | 60 | 50 | 110 |
| Not reported | 2 | 8 | 10 |
| Region of Enrollment(Participants) | Brentuximab Vedotin | Methotrexate or Bexarotene | Total |
|---|---|---|---|
| Australia | 12 | 8 | 20 |
| Belgium | 4 | 2 | 6 |
| France | 4 | 3 | 7 |
| Germany | 3 | 2 | 5 |
| Italy | 12 | 6 | 18 |
| Poland | 2 | 1 | 3 |
| Spain | 2 | 3 | 5 |
| Switzerland | 3 | 3 | 6 |
| United Kingdom | 8 | 15 | 23 |
| United States | 14 | 17 | 31 |
| Brazil | 2 | 2 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jun 2012 to primary completion in May 2016, 47 months.
Results were first posted in Mar 2018, 1 year 9 months after primary completion. A results delay was requested in Feb 2017.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brentuximab Vedotin
Millennium Pharmaceuticals, Inc. →